Company type | Public | ||||||
---|---|---|---|---|---|---|---|
SSE: 600664 | |||||||
Industry | Pharmaceuticals | ||||||
Predecessor | Harbin Pharmaceutical Administration | ||||||
Founded | 1988 | ||||||
Headquarters | , China | ||||||
Area served | Worldwide | ||||||
Owner |
| ||||||
Number of employees | 20,100 (2014) | ||||||
Subsidiaries |
| ||||||
Chinese name | |||||||
Simplified Chinese | 哈药集团有限公司 | ||||||
Traditional Chinese | 哈藥集團有限公司 | ||||||
| |||||||
Shortened name | |||||||
Simplified Chinese | 哈药集团 | ||||||
Traditional Chinese | 哈藥集團 | ||||||
| |||||||
Website |
hayao | ||||||
Footnotes / references [1] |
Harbin Pharmaceutical Group Co., Ltd. (shortened to HPGC or Hayao) is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. [2] [3] [4] HPGC medication offerings include traditional Chinese medicine (TCM) and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. [5]
The company owns both Renmintongtai (人民同泰), a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products.
In 2007, HPGC obtained approximately 73% and 14% of its total revenue from the sale of Western medicines and TCM preparations, respectively.[ citation needed]
In February 2018, HPGC announced its intentions to purchase a 40% stake in GNC Holdings, Inc. for US$300 million, following GNC's filing for Chapter 11 bankruptcy. In September 2020, it wholly acquired the company for US$770 million. [6] [7]
HPGC manufactures and distributes products for GNC China (known as 健安喜; Jiàn'ānxǐ) under a joint venture, GNC (Shanghai) Food Technology Co., Ltd, formed in February 2019. [8]
In February 2022, HPGC was stripped of its National Enterprise Technology Center status, a state designation for enterprises identified as capable of extraordinary technology innovation, by the National Development and Reform Commission after failing to meet the previous year's qualification requirements. [9]
Company type | Public | ||||||
---|---|---|---|---|---|---|---|
SSE: 600664 | |||||||
Industry | Pharmaceuticals | ||||||
Predecessor | Harbin Pharmaceutical Administration | ||||||
Founded | 1988 | ||||||
Headquarters | , China | ||||||
Area served | Worldwide | ||||||
Owner |
| ||||||
Number of employees | 20,100 (2014) | ||||||
Subsidiaries |
| ||||||
Chinese name | |||||||
Simplified Chinese | 哈药集团有限公司 | ||||||
Traditional Chinese | 哈藥集團有限公司 | ||||||
| |||||||
Shortened name | |||||||
Simplified Chinese | 哈药集团 | ||||||
Traditional Chinese | 哈藥集團 | ||||||
| |||||||
Website |
hayao | ||||||
Footnotes / references [1] |
Harbin Pharmaceutical Group Co., Ltd. (shortened to HPGC or Hayao) is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. [2] [3] [4] HPGC medication offerings include traditional Chinese medicine (TCM) and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. [5]
The company owns both Renmintongtai (人民同泰), a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products.
In 2007, HPGC obtained approximately 73% and 14% of its total revenue from the sale of Western medicines and TCM preparations, respectively.[ citation needed]
In February 2018, HPGC announced its intentions to purchase a 40% stake in GNC Holdings, Inc. for US$300 million, following GNC's filing for Chapter 11 bankruptcy. In September 2020, it wholly acquired the company for US$770 million. [6] [7]
HPGC manufactures and distributes products for GNC China (known as 健安喜; Jiàn'ānxǐ) under a joint venture, GNC (Shanghai) Food Technology Co., Ltd, formed in February 2019. [8]
In February 2022, HPGC was stripped of its National Enterprise Technology Center status, a state designation for enterprises identified as capable of extraordinary technology innovation, by the National Development and Reform Commission after failing to meet the previous year's qualification requirements. [9]